Quest Diagnostics Stock Symbol DGX Financial Insights and Analysis

Quest Diagnostics is a well-established player in the healthcare industry, with a stock symbol of DGX. The company has a long history of providing diagnostic testing services to patients, physicians, and hospitals.

With a market capitalization of over $20 billion, Quest Diagnostics is a significant player in the industry. Its financial performance is a key indicator of its success.

Quest Diagnostics has a strong track record of profitability, with a net income margin of around 10% over the past few years. This is a testament to the company's ability to efficiently manage its operations and deliver value to its customers.

The company's revenue has been steadily increasing over the years, driven by the growing demand for diagnostic testing services.

Quest Diagnostics' financial performance has been consistently strong over the years, with a revenue growth of 5-6% annually.

The company's revenue reached $10.8 billion in 2020, a 5.4% increase from the previous year.

Quest Diagnostics has a market capitalization of around $14 billion, making it one of the largest medical laboratories in the world.

The price history of Quest Diagnostics is quite impressive. The current share price is a whopping $174.06.

Over the past year, the company's stock has seen a significant increase of 37.92%. This is a clear indication of the company's financial performance and growth.

In the past five years, Quest Diagnostics' stock has risen by a staggering 55.26%. This is a remarkable feat, especially considering the fluctuations in the market.

Here's a breakdown of the company's stock performance over the past few years:

The company's stock has also seen a notable increase of 12.09% in the past month and 7.27% in the past three months. This shows that the company's financial performance is consistent and stable.

DGX's price volatility has been relatively stable compared to the US market. In fact, it has not had significant price volatility in the past 3 months.

DGX's weekly volatility of 3% is significantly lower than the market average of 6.0%. This stability is a positive sign for investors.

Here's a comparison of DGX's volatility with other stocks in the US market:

DGX's stable share price is a testament to its consistent performance over time.

Diagnostics Estimates provide valuable insights into the financial performance of Quest Diagnostics. The company's revenue is expected to grow from $10,781 in 2025 to $12,151 in 2028.

According to the estimates, Quest Diagnostics' revenue is projected to increase by 5.5% in 2025 and 4.2% in 2026. This growth is expected to continue in 2027 with a 3.7% increase.

The estimates also suggest that the company's net profit will rise from $1,096 in 2025 to $1,414 in 2027. This increase in net profit is due to the company's ability to maintain a high gross income margin and reduce its operating expenses.

Here is a breakdown of the estimated revenue and net profit for Quest Diagnostics:

The estimates also indicate that Quest Diagnostics' EBITDA will increase from $2,168 in 2025 to $2,589 in 2027. This increase in EBITDA is due to the company's ability to maintain a high gross income margin and reduce its operating expenses.

The company's EPS (Non-GAAP) ex. SOE is expected to grow from $9.70 in 2025 to $12.73 in 2028. This increase in EPS is due to the company's ability to maintain a high gross income margin and reduce its operating expenses.

Quest Diagnostics stock is looking strong with a projected revenue growth of 11.2% in 2025, according to estimates. This growth is expected to continue through 2026 and 2027, with revenue projected to reach $12,151 and $12,727 respectively.

The company's dividend yield is also impressive, standing at 1.76% in 2025. This is a relatively stable figure, increasing slightly to 1.82% in 2026. Quest Diagnostics has a history of paying consistent dividends, with a payout ratio of around 35-40%.

Here's a breakdown of the projected earnings per share (EPS) for the next few years:

The company's P/E ratio is also expected to decrease, from 17.76 in 2025 to 13.53 in 2028. This could indicate that investors are becoming more optimistic about Quest Diagnostics' future prospects.

At Quest Diagnostics, the management team is led by James E. Davis, the Chairman, President & Chief Executive Officer.

The company has a diverse and experienced leadership team, with several key executives holding multiple roles. For example, Sam A. Samad serves as both Chief Financial Officer & Executive Vice President.

Quest Diagnostics has a strong focus on compliance, with Kristin Wallace serving as both Chief Compliance Officer & Senior Vice President.

Here is a list of some of the key executives at Quest Diagnostics:

The company also has a team of experienced independent directors, including Timothy L. Main, Denise M. Morrison, and Wright L. Lassiter.

Take a look at this: Sona B L W Share Price

When evaluating the performance of your investments, it's essential to consider the returns on your shares. DGX, a company in the US Healthcare industry, has delivered impressive returns.

DGX's 7-day return was 3.1%, significantly outperforming the US Market's -3.0% return over the same period.

The 1-year return for DGX was 37.9%, a stark contrast to the US Healthcare industry's -11.1% return.

Here's a summary of the returns for DGX and the US Market over the past year:

DGX also outperformed the US Market, which returned 17.8% over the past year.

Quest Diagnostics has received a range of opinions from analysts over the past year, with some maintaining a neutral stance and others upgrading their rating to a buy.

J.P. Morgan and UBS have both maintained a hold rating for Quest Diagnostics, with prices ranging from $170 to $180.

Mizuho, on the other hand, has maintained a buy rating for the company, with a price of $155 in April 2024.

Several analysts have upgraded their rating for Quest Diagnostics, including Jefferies & Company Inc. in February 2024, Bank of America Merrill Lynch in December 2023, and Citigroup Corp. in December 2023.

Here's a breakdown of the analyst opinions:

These upgrades suggest that some analysts are optimistic about Quest Diagnostics' future performance, but it's essential to consider multiple perspectives before making any investment decisions.

Quest Diagnostics' stock symbol is QGM. The company has made significant strides in its growth strategy, acquiring several companies to expand its services and reach.

Quest Diagnostics acquired Lab One Medical Group in 2016, expanding its presence in the Midwest. This acquisition added over 1,000 patients to Quest's network.

The company has continued to grow through strategic acquisitions, demonstrating its commitment to expanding its services and improving patient care.

Quest Diagnostics completed its acquisition of the outreach lab services business of University Hospitals. This move will benefit physicians and patients in Ohio.

Physicians will have access to Quest's industry-leading test menu. This expanded menu will provide them with a wider range of diagnostic options.

Patients in Ohio will benefit from Quest's broad health plan relationships. This means they'll have easier access to testing and diagnosis.

The acquisition was completed on January 27, 2025.

Organic growth is a key driver of Quest Diagnostics' success, as seen in their recent Q3 earnings report. They reported an 8.5% revenue increase, beating Street expectations.

This growth is particularly impressive given the company's established presence in the market. Quest Diagnostics has a strong base to build on, with benefits from an aging population driving increased lab testing volumes.

Their genetic testing services are likely a major contributor to this growth, as the demand for genetic testing continues to rise. This trend is expected to continue, providing a tailwind for the company's future growth.

The company's ability to raise its 2024 revenue guidance is a testament to its financial health and stability. This increased guidance suggests that Quest Diagnostics is well-positioned for continued success in the years to come.

Their 2.0% dividend yield is also a attractive feature for investors, providing a relatively stable source of income. This, combined with the company's strong growth prospects, makes Quest Diagnostics an appealing investment opportunity.

Quest Diagnostics' financial statements are publicly available, showing the company's revenue and net income.

The company's revenue has consistently increased over the years, reaching $9.3 billion in 2020.

Quest Diagnostics reported a net income of $1.1 billion in 2020, up from $944 million in 2019.

The company's financial statements also show a significant increase in its operating cash flow, from $1.4 billion in 2019 to $1.6 billion in 2020.

Quest Diagnostics' financial statements are a good indicator of the company's overall health and stability.

The company's ability to generate significant cash flow has enabled it to invest in new technologies and expand its services.

If this caught your attention, see: Ftse China 50 Net Tax Usd Index